Benjamin Hohl, CFO, on September 17, 2026, sold 6,018 shares in Enliven Therapeutics (ELVN) for $303,003. Following the Form 4 filing with the SEC, Hohl has control over a total of 38,000 common shares of the company, with 38,000 shares held directly.
SEC Filing: